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Abstract: Background: Diastolic dysfunction (DD) is associated with myocardial fibrosis mediated by inflammation. 
Higher levels of inflammation found in African Americans (AAs) may predict DD among asymptomatic individuals. We 
tested the hypothesis that high sensitivity C-reactive protein (hs-CRP), a biomarker of inflammation, is associated with 
DD in asymptomatic AAs.  
Methods:  We prospectively recruited 107 asymptomatic AAs without any history of cardiac, renal or inflammatory   
diseases or alcoholism. We measured hs-CRP and B-type Natriuretic peptide (BNP) levels and estimated left ventricular 
end diastolic pressure (LVEDP), mass and systolic function with echocardiography. Multivariate logistic regression 
analysis was used to define whether hs-CRP is an independent predictor of LVEDP.  
Results: Among 107 subjects: the mean age was 48±10 yrs, 58 (54%) were men, 59 (55%) had diabetes (DM), 48 (45%) 
had hypertension (HTN), the mean BMI was 30.5±4.8 and the mean ejection fraction was 63.1±5.8%. DD was present  
in 56(52%) subjects, 38 (36%) of whom also had a high LVEDP. On multivariate analysis, hs-CRP was independently  
associated with DD [odds ratio 3.36 (95% CI= 1.07 - 10.5, p = 0.04]. There was a 61% and 133% increase in the  
prevalence of any DD and DD with high LVEDP, respectively, between the lowest and the highest hs-CRP quartiles.  
Conclusion: Diastolic dysfunction is prevalent among asymptomatic African Americans and it is independently associated 
with elevated level of hs-CRP, an inflammation marker.  
Keywords: Diastolic dysfunction, Inflammation, High sensitivity C-reactive protein, Biomarkers. 
INTRODUCTION 
  Diastolic dysfunction (DD) is the predominant patho-
physiological mechanism in a third of the heart failure popu-
lation [1-6]. Inflammatory fibrosis of the myocardium is 
thought to be a major cause of myocardial stiffening leading 
to the development of DD. The higher prevalence of proin-
flammatory conditions such as diabetes (DM) and hyperten-
sion (HTN) and the higher levels of inflammatory markers 
often found in African Americans (AA) may predispose 
them to myocardial stiffening and DD, ultimately resulting 
in symptomatic heart failure [7-11]. We conducted this cross  
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sectional study to test the hypothesis that high sensitivity   
C-reactive protein (hs-CRP), a biomarker of inflammation, is 
associated with DD and is a clinical predictor of incipient 
diastolic heart failure in asymptomatic AA subjects. 
METHODS 
Study Subjects 
  We prospectively screened 135 AAs between the ages of 
20 and 65 years with no known history of heart disease or 
cardiovascular symptoms who visited an outpatient walk-in 
clinic between March 2004 and May 2006 at an urban 
healthcare center in Chicago. Of those 117 were included in 
the study (18 declined to participate) (Fig. 1). They pre-
sented to the clinic for medications for their underlying 
chronic conditions or for unrelated medical problems. A HS-CRP and Diastolic Dysfunction  The Open Cardiovascular Medicine Journal, 2011, Volume 5    189 
standardized interview and physical exam was administered 
to all subjects. Blood pressure was measured using estab-
lished methods [12]. HTN was defined as a systolic blood 
pressure 140 mm Hg and/or a diastolic blood pressure > 90 
mm Hg or receiving antihypertensive drug therapy [13]. 
Subjects were classified as having DM if they had a history 
of type 2 diabetes diagnosed with the American Diabetic 
Association criteria or were on medications for diabetes [14]. 
We successfully recruited approximately equal number of 
subjects who had HTN and DM, DM only, HTN only and 
neither HTN nor DM as planned.  
  Subjects were excluded if they had signs and symptoms 
of heart failure or other cardiac symptoms, history of prior 
cardiovascular diseases (myocardial infarction, coronary 
artery disease, heart failure, valvular heart disease, arrhyth-
mia, bundle branch block, wall motion abnormalities on ear-
lier echo, stroke, and peripheral vascular disease), newly 
diagnosed (less than one year) DM or HTN or type 1 DM, 
serum creatinine  1.6 mg/dl, history of cocaine or heroin 
use in the last 6 months, alcoholism (defined as at least two 
positive responses to CAGE questionnaire), [15] body mass 
index (BMI) 18.5 or 40 and conditions associated with 
acute hs-CRP elevation (those with signs of acute systemic 
infection/inflammation such as fever or the use of estrogens 
in any form) [16-19].  
  Laboratory measurements included serum creatinine lev-
els, hemoglobin A1C (HbA1c), b-type natriuretic peptide 
(BNP) (Advia Centaur Immunoassay systems, Bayer diag-
nostics, New York, USA) and hs-CRP levels (Immulite 2000 
immunometric assay, DPC, California, USA). Any value 
below the lowest possible measurement of BNP (< 0.5 pg/dl) 
and hs-CRP value (<0.02 mg/dl) was considered zero. All 
subjects provided written informed consent. The Scientific 
Research Committee of the hospital approved this study. 
This human investigation conforms to the principles outlined 
in the Declaration of Helsinki. 
Echocardiography 
  M-mode, 2D, Doppler and tissue Doppler imaging was 
performed on all subjects using standard techniques. Ejection 
fraction and wall motion abnormalities were assessed visu-
ally. Measurements of interventricular septal thickness 
(IVST), posterior wall thickness (PWT) and left ventricular 
internal diameter (LVID) were made at end-diastole and end-
systole according to the American Society of Echocardi-
ography (ASE) recommendations [20]. Left ventricular (LV) 
mass was calculated using the ASE formula with Devereux’s 
correction and raised to the power 2.7 (LV mass index-
LVMI) to minimize the errors in estimating the impact of 
overweight [21, 22].  
  All participants had a pulsed-wave Doppler examination 
of
 mitral inflow and of pulmonary
 venous inflow. Doppler 
velocities
 of early (E) and late diastolic mitral flow (A), the 
deceleration time
 (DT) and the E/A ratio (including  E/A 
ratio with Valsalva maneuver) were measured. Pulmonary 
venous peak systolic flow velocity and diastolic flow veloc-
ity were also obtained [23]. Tissue Doppler imaging was 
obtained at the medial mitral annulus. The early (e) and late 
diastolic velocities (a') were determined and the ratio of   
the transmitral flow velocity and annular velocity (E/e')
 was 
performed to assess LV end diastolic pressure (LVEDP). 
The prediction of elevated filling pressure was primarily 
based on E/e’ ratio > 10 and a decrease in E/A ratio by   
0.5 with Valsalva maneuver [24]. Subjects with E/e' 10 
were considered to have normal LVEDP [25-27].  
Classification of Diastolic Dysfunction 
  Using standard criteria for Doppler measurements of mi-
tral inflow, pulmonary venous flow and tissue velocities, 
diastolic function was categorized into normal, DD with 
normal LVEDP (DD1) (impaired relaxation, also known as 
grade-1 DD) and
 DD with high LVEDP (DD2) . The latter 
group includes subjects with impaired relation with elevated 
LVEDP (also known as grade-1B), pseudonormal filling 
pattern (grade-2 DD) and advanced DD (grade 3, restrictive 
filling pattern) [3, 23]. LVEDP and diastolic function classi-
fication were adjudicated by a cardiologist who is an expert 
in echocardiographic assessment of diastolic function. Rules 
utilized in predicting LVEDP and diastolic function classifi-
cation are consistent with the subsequently published rec-
ommendations of American Society of Echocardiography 
[28].  
Statistical Analysis 
  Association of DD1, DD2 or E/e' ratio with hs-CRP   
was determined controlling for the effects of possible   
confounders (age, sex, diabetes, hypertension, BMI and 
LVM index) and that of BNP. Separate logistic regression 
analyses were used to determine association of DD1 or DD2 
with hs-CRP, BNP, age, sex, BMI, LVM index, DM, or 
HTN unadjusted for any other factor. Multiple logistic   
regression analysis was used to determine association of 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Study Scheme DD - diastolic dysfunction, DM – diabetes 
mellitus, hs-CRP = high sensitivity C-reactive, HTN – hyperten-
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DD1 or DD2 with hs-CRP controlling for the effects of   
significant confounders and BNP. The assumptions and   
validity of the logistic regression model was ascertained 
(model fitting information, goodness of fit). Spearman rank 
correlation was used to determine unadjusted correlation 
between E/e' ratio and hs-CRP while the Wilcoxon rank   
sum test was used to determine association of E/e' ratio   
with sex, DM and HTN by comparing average value of   
E/e' ratio between categories of these possible confounders. 
The general linear model was used to determine significant 
association between E/e' ratio and hs-CRP adjusted for the 
effects of significant confounders and BNP. The quartiles for 
hs-CRP were compared for prevalence of (DD1) and (DD2) 
using the chi-square test.  
RESULTS 
  In all, of 117 subjects recruited, 107 completed the study 
procedures (9 had incomplete data and 1 met exclusion   
criteria, Fig. 1). The baseline characteristics are presented in 
Table 1. Echocardiogram revealed any DD in 56 (52%) of 
these asymptomatic individuals: 18 (17%) had mild DD 
(DD1) with normal LVEDP (E/e ratio 10) and 38 (36%) 
had DD with elevated LVEDP (DD2) [E/e ratio >10 and a 
decrease in E/A ratio by 0.5 with Valsalva maneuver]. 
Table 1.  Baseline Characteristics 
Characteristics  Participants (n = 107) 
Age (yrs) (mean ± SD)  48±10 
Men 58  (54%) 
Diabetic not hypertensive  32 (30%) 
Hypertensive not diabetic  21 (20%) 
Diabetic hypertensive  27 (25%) 
Not diabetic not hypertensive  27 (25%) 
Body mass index (kg/m2) (mean ± SD)  30.5±4.8 
Systolic blood pressure (mm Hg) (mean ± SD)  124±17 
Diastolic blood pressure (mm Hg) (mean ± SD)  78±11 
Glycosylated hemoglobin HbA1c (%) (mean ± SD)  7.9±2.5 
hs-CRP levels (mg/dl) (mean) (range)  0.5 (0.02-4.65) 
hs-CRP levels (mg/dl) (<25
th percentile)  0.1 
hs-CRP levels (mg/dl) (25
th-75
th percentile)  0.11 – 0.61 
hs-CRP levels (mg/dl) (>75
th percentile)  0.614 
BNP levels (pg/dl)  18.7 (0-180) 
LV mass (gm)  158±49 
LVMI (gm/m
2.7) 38±11.4 
Ejection fraction (mean ± SD)  63.1±5.8% 
BNP = b-type natriuretic peptide, hs-CRP = high sensitivity C-reactive protein, LV = 
left ventricle, LVMI = left ventricular mass index. 
  Univariate analyses of various factors associated with 
DD1 and DD2 were made and the results are shown in Table 2. 
Age, BMI, HTN and LVMI were significant confounding 
factors for the association between hs-CRP and DD2 and 
E/e ratio. These same factors except BMI were the signifi-
cant confounding factors for the association between hs-CRP 
and DD1. There was no significant association between BNP 
and DD1 (p=0.66), DD2 (p=0.16) or E/e ratio (p=0.61) and 
hence were not included in the multivariate analysis.  
 Table  3 shows significant association between hs-CRP 
and DD1 (p=0.04), DD2 (p=0.02), and E/e ratio (p=0.006) 
adjusted for the effects of confounding factors in the multi-
variate analysis. For every unit increase in hs-CRP, there 
were significant increases of 3.36% and 3.62% in odds for 
DD1 and DD2, respectively, adjusted for the effect of con-
founding factors. There was a significant contribution of hs-
CRP to the observed variability of E/e ratio (F ratio of mean 
square for hs-CRP to mean square for error=7.93) control-
ling for the effects of confounding factors. Independent risk 
factors for DD2 and E/e ratio were age, LVM index and hs-
CRP whereas only age and hs-CRP were the independent 
risk factors for DD1. 
  There was an overall significant difference in overall all 
prevalence of any DD (p=0.03) and DD2 (p=0.003) rates 
among the hs-CRP quartile groups. There were significant 
pair wise differences among the hs-CRP groups 1 and 3 
(p=0.008) and between groups 2 and 3 (0.001) in rate of   
occurrence of DD (Fig. 2). 
  Of all the participants 3 were found to have mild upper 
respiratory infection with no fever or systemic symptoms. 
Exclusion of these participants from the analysis did not 
change the outcome. 
DISCUSSION 
  Myocardial stiffness and DD can result from cardiac   
fibrosis caused by the increased deposition of collagen in   
the interstitium mediated in part by inflammatory processes 
[1, 29, 30]. Small studies have suggested that low-grade   
systemic inflammation is associated with high arterial   
stiffness, which in turn is associated with the stiffening of 
the ventricle and diastolic heart failure [31-34]. African 
American subjects have a higher prevalence of proinflamma-
tory conditions like DM and HTN, which puts them at a risk 
of an earlier onset and accelerated progression of arterial 
stiffness and are at high risk for diastolic dysfunction [35].  
  In the present study of asymptomatic AA subjects, the 
prevalence of DD including those with high LVEDP was 
very high (56%). DD to this degree in a relatively young 
population may be of considerable clinical importance, since 
the presence of DD is a powerful predictor of symptomatic 
heart failure and all-cause mortality [3, 36]. The most impor-
tant finding of the present study is the strong association 
between DD and elevated hs-CRP levels, independent of 
DM, HTN, BMI, and LV hypertrophy. It is also important to 
note that those with higher hs-CRP levels tend to have more 
advanced DD with elevated LVEDP. Others have reported 
an association between hs-CRP levels and LVEDP in pa-
tients with heart failure [37]. Our data suggests that this as-
sociation appears to exist even in those with asymptomatic HS-CRP and Diastolic Dysfunction  The Open Cardiovascular Medicine Journal, 2011, Volume 5    191 
DD. The strong independent association between hs-CRP 
levels, a well-established marker of inflammation and DD 
may indicate that inflammation plays a prominent role in the 
development of DD. It was also interesting to note that the 
BNP levels were not significantly associated with DD in this 
asymptomatic population. It has been noted by others as well 
that in asymptomatic population with diastolic dysfunction 
BNP may not always be elevated [38, 39].  
Table 2.  Factors Associated with Diastolic Dysfunction by Univariate Analysis 
  Factors Significantly Associated with Outcomes Odds Ratio (95% CI)  p-value 
Age: OR=1.19 (1.11 to 1.27)  <0.01 
HTN: OR=7.14 (2.94 to 16.67)  <0.01 
LVM Index: OR=1.07 (1.03 to 1.12)  <0.01 
DD1 
Hs-CRP: OR=3.94 (1.32 to 11.72)   0.014 
Age: OR=1.12 (1.06 to 1.19)  <0.01 
HTN: OR=5.56 (2.38 to 12.50)  <0.01 
BMI: OR=1.11 (1.02 to 1.21)  0.02 
LVM Index: OR=1.09 (1.04 to 1.14)  <0.01 
DD2 
Hs-CRP: OR=4.35 (1.61 to 11.77)   <0.01 
Age: Spearman rank correlation coefficient = 0.423  <0.01 
LVM: Spearman rank correlation coefficient = 0.402  <0.01 
BMI: Spearman rank correlation coefficient = 0.234  0.02 
Hs-CRP: Spearman rank correlation coefficient = 0.340   <0.01 
E/e’ 
HTN: 10.8±3.3 (Yes) vs. 8.3±2.9 (No) [comparison of means]  <0.01 
BMI = body mass index, Hs-CRP = high sensitivity C-reactive protein, HTN = hypertension, LVMI = left ventricular mass index, DD = diastolic dysfunction. 
 
Table 3.  Factors Associated with Diastolic Dysfunction after Adjusting for the Effect of Confounders 
DD Outcome  Factors Associated with DD Adjusted for the Effects of other Factors   p-value 
hs-CRP: OR=3.36 (1.07 to 10.52)  0.04* 
Age: OR=1.16 (1.08 to 1.25)  <0.01** 
LVM: OR=1.04 (0.99 to 1.10)  0.15
NS 
DD1 
HTN: OR=2.17 (0.72 to 6.25)  0.17
NS 
hs-CRP: OR=3.62 (1.78 to 10.23)  0.02* 
Age: OR=1.10 (1.03 to 1.17)  0.006** 
LVM: OR=1.07 (1.01 to 1.13)  0.02* 
HTN: OR=1.65 (0.55 to 5.00)  0.36
NS 
DD2 
BMI: OR=0.99 (0.89 to 1.11)  0.84
NS 
hs-CRP: MS
1=61.03, F
2=7.89 0.006** 
Age: MS=61.35 , F=7.93  0.006** 
LVM: MS=45.76, F=5.92  0.02* 
HTN: MS=7.97, F=1.03  0.31
NS 
DD3 
BMI: MS=.04, F=.01  0.94
NS 
**Significant at 1% level of significance (p-value<0.01), *Significant at 5% level of significance (0.01<p-value<0.05), 
NSNot Significant at 5% level of significance (p-value>0.05), 
1MS – Mean Square for factor in general linear regression model, 
2F – Ratio of MS (factor) to mean square error for testing significant effect of factor on E/e ratio BMI = body mass 
index, Hs-CRP = high sensitivity C-reactive protein, HTN = hypertension, LVMI = left ventricular mass index, DD = diastolic dysfunction 192    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Rajaram et al. 
  We conclude that hs-CRP appeared to be an important 
clinical predictor of DD in this cohort independent of the 
other clinical predictors of DD like age, HTN, DM and BNP. 
Therefore, it may be another potential biomarker of incipient 
heart failure.  
Mechanism of Association between Inflammation   
and DD 
  Myocardial fibrosis in diastolic heart failure is character-
ized by poorly structured and fractured collagen in the ex-
tracellular matrix (ECM) [10, 29, 40, 41]. Matrix metallopro-
teinases (MMP) are enzymes released by macrophages and 
fibroblasts, which modulate the remodeling of the ECM [41, 
42]. These MMPs and the tissue inhibitors of matrix metal-
loproteinases (TIMPs) are in turn regulated by inflammatory 
cytokines such as C-reactive protein [41, 43, 44].  
  Further support to the etiological role of inflammation in 
causing DD comes from animal studies where normalization 
of DD was achieved using anti-inflammatory agents inde-
pendent of the resolution of LV hypertrophy [45, 46]. In-
flammation has been proposed to be a common pathway 
through which conditions like HTN and DM lead to ven-
tricular stiffness and DD and eventually to decompensated 
heart failure. 
  Alternatively it can be speculated based on current body 
of evidence that elevated hs-CRP may be either a marker or 
mediator of impaired coronary blood flow reserve which is 
known to be associated with ventricular fibrosis and diastolic 
dysfunction [47-49].  
  With the increase in DM, HTN and obesity, the preva-
lence of DD is likely to increase in the near future. To date, 
the management of DD in clinical practice is based mostly 
on our knowledge of the pathophysiology and trial data in 
established diastolic heart failure [50]. There are few specific 
interventions to reverse DD and to prevent the development 
of symptomatic heart failure once DD is detected. If the as-
sociation between inflammation and DD can be confirmed 
by further study in humans, controlling inflammation could 
be a target for therapy for DD and possibly for the preven-
tion of symptomatic heart failure [51]. The hs-CRP level also 
has the potential to be useful in identifying those at risk for 
DD and possibly predict those who are likely to progress to 
symptomatic heart failure, pending confirmation by prospec-
tive and long-term observational studies.  
STUDY LIMITATIONS 
  We recruited patients for this study from an outpatient 
walk-in clinic of an inner-city hospital. Many patients visit 
this facility to obtain medication refills for their underlying 
chronic condition. This may explain the high proportion of 
patients with type-2 DM, as these individuals may have dis-
proportionately frequented the clinic for the sole purpose of 
obtaining a medication refill. Additionally, this fact would 
suggest that patients recruited may have been sub-optimally 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Rates of DD by hs-CRP quartiles. Overall DD and DD2 rates were significantly different among the hs-CRP quartile groups (p=0.03 
and p=0.003 respectively). There were significant pair wise differences among the hs-CRP quartile groups 1 and 3 (p=0.008) and groups 2 
and 3 (0.001) in the rate of occurrence of any DD. HS-CRP and Diastolic Dysfunction  The Open Cardiovascular Medicine Journal, 2011, Volume 5    193 
managed for their underlying chronic condition as they util-
ized an urgent care center rather than a steady primary care 
physician to treat these conditions. Possibly, we may have 
included patients who ran out of their antihypertensive or 
DM medications with subsequent acute changes in their 
blood pressure or glucose level altering their diastolic func-
tion [52]. We acknowledge the possibility of these factors 
affecting the prevalence of DD among the enrolled subjects. 
Nevertheless, these selection biases do not explain the   
observed correlation between DD, elevated LVEDP and   
hs-CRP in asymptomatic patients. Furthermore, the biolo- 
gical plausibility reasoning we outlined in our discussion 
justifies further examination of our findings. 
  This was a cross sectional study with a single measure-
ment of hs-CRP levels. Hence this study did not capture in-
herent variability of hs-CRP levels introduced by moderate 
alcohol consumption, increased activity and exercise, medi-
cations and other unknown variables or linear trends in hs-
CRP levels [53]. This limitation may explain the presence of 
DD in those with low hs-CRP levels. Alternatively there may 
be other markers of inflammation (e.g. IL-6) or collagen 
metabolism that could be more closely associated with DD. 
This study did not measure any other inflammatory markers 
or markers of collagen metabolism. It is likely that there are 
also non-inflammatory factors associated with DD. A pro-
spective longitudinal study with serial measurement of hs-
CRP levels and other markers of inflammation and collagen 
metabolism is needed to address these issues. Also the study 
population was not tested for underlying coronary artery 
disease, which could also have an inflammatory origin and 
present as diastolic dysfunction. It was not considered neces-
sary to subject an asymptomatic population to further risky 
or invasive testing in the absence of specific therapy other 
than modifying risk factors. Besides the purpose of this   
study is to report the association between inflammation and 
diastolic dysfunction in this population and delineating the 
mechanism of association is beyond the scope of this study. 
CONCLUSION  
  Our data establishes a strong and independent association 
between hs-CRP levels and the presence of DD in asympto-
matic AAs, which supports the concept of systemic inflam-
mation as an etiological factor in myocardial fibrosis and LV 
dysfunction. If confirmed by larger, longitudinal studies this 
association may have implications in identifying the popula-
tion at risk for heart failure and for possible new targets   
for treatment of DD and prevention of symptomatic heart 
failure. Hs-CRP levels may also identify individuals with 
advanced DD. 
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ABBREVIATIONS  
DD =  Diastolic  dysfunction 
DD1  =  DD w/normal LVEDP 
DD2  =  DD with high LVEDP 
AA =  African  Americans 
hs-CRP  =  High sensitivity C-reactive protein 
DM =  Diabetes 
HTN =  Hypertension 
BNP  =  B-type natriuretic peptide 
LVEDP  =  Left ventricular end diastolic pressure 
HbA1c =  Hemoglobin  A1C 
BNP  =  Brain natriuretic peptide 
IVST  =  Interventricular septal thickness 
PWT =  Posterior  wall  thickness 
LVID  =  Left ventricular internal diameter 
ASE  =  American Society of Echocardiography 
LV =  Left  ventricular 
LVMI  =  Left Ventricular mass index 
DT =  Deceleration  time 
MMP =  Matrix  metalloproteinases 
TIMPs  =  Tissue inhibitors of matrix metalloprotein-
ases 
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